Avapritinib reduced cutaneous symptoms and mast cell (MC) burden in patients (pts) with indolent systemic mastocytosis (ISM) in the PIONEER study
2020
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI